There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Regeneron (REGN – Research Report) and Phasebio Pharmaceuticals (PHAS – Research Report) with bullish sentiments.
In a report released today, Hartaj Singh from Oppenheimer assigned a Buy rating to Regeneron, with a price target of $725.00. The company’s shares closed last Tuesday at $489.02.
According to TipRanks.com, Singh is a 5-star analyst with an average return of 15.5% and a 49.0% success rate. Singh covers the Healthcare sector, focusing on stocks such as Opthea Limited Sponsored ADR, Catabasis Pharmaceuticals, and Vertex Pharmaceuticals.
Regeneron has an analyst consensus of Moderate Buy, with a price target consensus of $658.36.
Phasebio Pharmaceuticals (PHAS)
Needham analyst Chad Messer assigned a Buy rating to Phasebio Pharmaceuticals today and set a price target of $19.00. The company’s shares closed last Tuesday at $5.13.
According to TipRanks.com, Messer is a 4-star analyst with an average return of 10.0% and a 50.5% success rate. Messer covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Autolus Therapeutics, and Sarepta Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Phasebio Pharmaceuticals with a $15.00 average price target, representing a 272.2% upside. In a report issued on March 11, William Blair also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.